🇺🇸 FDA

Company profile · Sponsor

Olema

Olema Pharmaceuticals

OLMA · NYSE pharma SAN FRANCISCO, CA, USA
Pipeline
7
Drugs
0
Patents
8

Quick answer

Olema (OLMA) is a pharma company. headquartered in SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker OLMA
Exchange NYSE
Company type pharma
Headquarters SAN FRANCISCO, CA, USA
SEC CIK 0001750284

Pipeline (7)

Search pipeline →

  1. Palazestrant

    Olema

    Breast Cancer

    phase 3 small molecule active

    3 trials

  2. Palazestrant matching placebo tablets and Letrozole matching placebo capsules, Palazestrant, RIBOCICLIB, Palazestrant, -, LETROZOLE , Palazestrant

    Olema

    ER+, HER2- Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  3. Palazestrant, FULVESTRANT, Palazestrant, EXEMESTANE, GOSERELIN , LETROZOLE, Palazestrant, Palazestrant, ANASTROZOLE

    Olema

    ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy

    phase 3 small molecule active

    1 trial

  4. OP-1250

    Olema

    Hormone Receptor Positive Breast Carcinoma

    phase 2 small molecule completed

    1 trial

  5. OP-3136

    Olema

    Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

    phase 1 small molecule active

    1 trial

  6. Palazestrant

    Olema

    Metastatic Breast Cancer

    phase 1 small molecule active

    1 trial

  7. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    Olema

    Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

Patents (8)

Search patents →

  1. US 12428379

    Acylsulfonamide KAT6A inhibitors

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12370181

    Regimens of estrogen receptor antagonists

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11672785

    Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11229630

    Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10624878

    Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

    Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10292971

    Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs

    Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9018244

    Benzopyran compounds, compositions and uses thereof

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8071545

    Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism

    Expires Mon Dec 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Olema?

Olema (OLMA) is a pharma company. headquartered in SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Olema sponsor?

We track 7 ClinicalTrials.gov-linked programs for Olema, including Palazestrant and 6 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Olema company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.